Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis

被引:43
作者
Aljiffry, Murad [1 ,2 ]
Renfrew, Paul D. [3 ]
Walsh, Mark J. [3 ]
Laryea, Marie [3 ]
Molinari, Michele [3 ]
机构
[1] McGill Univ, Ctr Hlth, Sect Hepatopancreaticobiliary & Transplant Surg, Montreal, PQ, Canada
[2] King Abdulaziz Univ, Dept Surg, Coll Med, Jeddah 21413, Saudi Arabia
[3] Dalhousie Univ, Dept Surg, Queen Elizabeth Hlth Sci Ctr 2, Halifax, NS B3H 4H2, Canada
关键词
primary sclerosing cholangitis; dominant stricture; cholangiocarcinoma; DIA; FISH; endoscopic ultrasound; ERCP MRCP CT cholangiography; biliary stenting; biliary dilatation; ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY; SERUM TUMOR-MARKERS; URSODEOXYCHOLIC ACID; LIVER-TRANSPLANTATION; DETECTING CHOLANGIOCARCINOMA; EXTRAHEPATIC MALIGNANCIES; MAGNETIC-RESONANCE; BRUSH CYTOLOGY; STENOSES; THERAPY;
D O I
10.1111/j.1477-2574.2010.00268.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background: The diagnosis and treatment of indeterminate dominant strictures (DS) in patients with primary sclerosing cholangitis (PSC) is challenging and the literature on the subject is scarce. Objectives: This review aims to appraise and synthesize the evidence published in the English-language medical literature on this topic. Methods: Scientific papers published from 1950 until week 4 of July 2010 were extracted from MEDLINE, Ovid Medline In-Process, the Cochrane Database of Systematic Reviews, the Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, EMBASE, PubMed and the National Library of Medicine Gateway. Results: Strategies for the optimal management of DS in PSC patients are supported only by level II and III evidence. Intraductal endoscopic ultrasound appears to be the most sensitive (64%) and specific (95%) diagnostic test for the evaluation of DS in PSC. Endoscopic and percutaneous dilatations achieve 1- and 3-year palliation in 80% and 60% of patients, respectively. Although dilatation and stenting are the most common palliative interventions in DS, no randomized trials on the optimal duration of treatment have been conducted. Conclusions: In benign DS, endoscopic dilatation with short-term stenting seems to be effective and safe and does not increase the risks for malignant transformation or complications after liver transplantation. Surgical bile duct resection and/or bilioenteric bypass are indicated only in patients with preserved liver function.
引用
收藏
页码:79 / 90
页数:12
相关论文
共 83 条
[1]
Primary sclerosing cholangitis - Resect, dilate, or transplant? [J].
Ahrendt, SA ;
Pitt, HA ;
Kalloo, AN ;
Venbrux, AC ;
Klein, AS ;
Herlong, HF ;
Coleman, J ;
Lillemoe, KD ;
Cameron, JL .
ANNALS OF SURGERY, 1998, 227 (03) :412-423
[2]
Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis [J].
Ahrendt, SA ;
Pitt, HA ;
Nakeeb, A ;
Klein, AS ;
Lillemoe, KD ;
Kalloo, AN ;
Cameron, JL .
JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (04) :357-367
[3]
Surgical approaches to strictures in primary sclerosing cholangitis [J].
Ahrendt, Steven A. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (03) :423-425
[4]
Serum autoantibodies in patients with primary sclerosing cholangitis [J].
Angulo, P ;
Peter, JB ;
Gershwin, ME ;
DeSotel, CK ;
Shoenfeld, Y ;
Ahmed, AEE ;
Lindor, KD .
JOURNAL OF HEPATOLOGY, 2000, 32 (02) :182-187
[5]
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis [J].
Baluyut, AR ;
Sherman, S ;
Lehman, GA ;
Hoen, H ;
Chalasani, N .
GASTROINTESTINAL ENDOSCOPY, 2001, 53 (03) :308-312
[6]
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community [J].
Bambha, K ;
Kim, WR ;
Talwalkar, J ;
Torgerson, H ;
Benson, JT ;
Therneau, TM ;
Loftus, EV ;
Yawn, BP ;
Dickson, ER ;
Melton, LJ .
GASTROENTEROLOGY, 2003, 125 (05) :1364-1369
[7]
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis [J].
Bergquist, A ;
Ekbom, A ;
Olsson, R ;
Kornfeldt, D ;
Lööf, L ;
Danielsson, Å ;
Hultcrantz, R ;
Lindgren, S ;
Prytz, H ;
Sandberg-Gertzén, H ;
Almer, S ;
Granath, F ;
Broomé, U .
JOURNAL OF HEPATOLOGY, 2002, 36 (03) :321-327
[8]
Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis [J].
Bergquist, A ;
Broomé, U .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (04) :643-656
[9]
Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis [J].
Berstad, AE ;
Aabakken, L ;
Smith, HJ ;
Aasen, S ;
Boberg, KM ;
Schrumpf, E .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (04) :514-520
[10]
URSODEOXYCHOLIC ACID FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - A PLACEBO-CONTROLLED TRIAL [J].
BEUERS, U ;
SPENGLER, U ;
KRUIS, W ;
AYDEMIR, U ;
WIEBECKE, B ;
HELDWEIN, W ;
WEINZIERL, M ;
PAPE, GR ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
HEPATOLOGY, 1992, 16 (03) :707-714